抗PD-1 [5C4.B8 (Nivolumab)]組換え抗体 | Anti-PD-1 [5C4.B8 (Nivolumab)] recombinant antibody
掲載日情報：2019/10/24 現在Webページ番号：218900
Absolute Antibody社の抗PD-1 [5C4.B8 (Nivolumab)]組換え抗体(リコンビナント抗体)( Anti-PD-1 [5C4.B8 (Nivolumab)] recombinant antibody)です。
※本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
価格
[在庫・価格 ：2025年05月17日 00時01分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anti-PD-1, Human-Mono [5C4.B8 (Nivolumab)], IgM, Purified Recombinant Antibody |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Anti-PD-1, Human-Mono [5C4.B8 (Nivolumab)], IgM, Purified Recombinant Antibody |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2025年05月17日 00時01分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Anti-PD-1, Human-Mono [5C4.B8 (Nivolumab)], IgM, Purified Recombinant Antibody
文献数： 0
- 商品コード：Ab00791-15.0
- メーカー：ABA
- 包装：50μg
- 価格：¥188,000
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | 別名：CD279，programmed death-1，programmed death 1，PD1，PD 1，Programmed cell death protein 1，hPD-1，hPD1，hPD 1，BMS-936558，MDX-1106，ONO-4538 クローン：5C4.B8 |
||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | -20℃ | 法規備考 | |
| 抗原種 | 免疫動物 | ||
| 交差性 | Cynomolgus/Human | 適用 | Blocking,FCM,IHC,SPR |
| 標識 | Unlabeled | 性状 | |
| 吸収処理 | クラス | IgM | |
| クロナリティ | Recombinant | フォーマット | |
| 掲載カタログ |
|
||
| 製品記事 | |||
| 関連記事 | |||
Anti-PD-1, Human-Mono [5C4.B8 (Nivolumab)], IgM, Purified Recombinant Antibody
文献数： 0
- 商品コード：Ab00791-15.0-BT
- メーカー：ABA
- 包装：500μg
- 価格：ご照会ください
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | 別名：CD279，programmed death-1，programmed death 1，PD1，PD 1，Programmed cell death protein 1，hPD-1，hPD1，hPD 1，BMS-936558，MDX-1106，ONO-4538 クローン：5C4.B8 |
||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | 法規備考 | ||
| 抗原種 | 免疫動物 | ||
| 交差性 | Cynomolgus/Human | 適用 | Blocking,FCM,IHC,SPR |
| 標識 | Unlabeled | 性状 | |
| 吸収処理 | クラス | IgM | |
| クロナリティ | Recombinant | フォーマット | |
| 掲載カタログ |
|
||
| 製品記事 | |||
| 関連記事 | |||
カートに商品を
追加しました。
追加しました。
製品情報
| Description | Recombinant monoclonal antibody to PD-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5C4.B8 (Nivolumab). This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. |
|---|---|
| Species and Isotype | Human IgM, kappa |
| Clone Number | 5C4.B8 (Nivolumab) |
| UniProt Accession Number of Target Protein | Q15116 |
| Published Application(s) | IHC; FC; SPR; block |
| Published Species Reactivity | Human; cynomolgus |
| Immunogen | mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein onsisting of the extracellular domain of PD-1 (amino acids 1–167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies). |
| Specificity | Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. The epitope of Nivolumab for both human and cynomolgus PD-1 includes the sequences SFVLNWYR-MSPSNQTDKLAAFPEDR (aa 29-53) and SGTYLCGAISLAPKAQIKE (aa 85-103), as shown by mass spectrometry of protease-treated fragments of PD-1 - these residues are thought to additionally be important for liand binding to PD-1. PD-1 is an inhibitory receptor expressed on the surface of T cells. It is able to bind to its ligands PDL-1 and PDL-2 which results in an inhibitory signal leading to decreased T cell proliferation, cytokine protuction and cytotoxic activtiy. PDL-1 is often expressed in human tumors such as melanoma, lung and kidney where it is able to overactivate PD-1 and plays a role in the evasion of cancer cells from the immune system. |
| Application Notes | Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNγ release, and also enhances IL-2 secretion (97-139% over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (~1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity). |
| Antibody First Published in | Wang et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In VivoToxicology in Non-Human Primates Cancer Immunol Res. 2014 Sep;2(9):846-56. PMID:24872026 |
| Note on publication | Describes the generation and characterization of the anti-PD-1 antibody nivolumab, including its specicity, binding affinity and its in vivo and in vitro properties. |
| Purification | Affinity Purified using a recombinant lectin column |
| Supplied in | Standard size: PBS with 0.02% Proclin 300. Bulk size: PBS only. |
| Storage Recommendation | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C |
| Concentration | See vial label. |
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。